Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 3.11 is 26% below its 5-year average of 4.19, near the low end of its 5-year range (2.52–7.67).
45.49% below its 12-month average of 5.71.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.53.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-09-09T20:00:00.000Z. Historical observations retain their original dates. Historical series through 2026-09-09.
EARNINGS PER SHARE (EPS)
3.11
EARNINGS PER SHARE (EPS) AVG TTM
5.71
EARNINGS PER SHARE (EPS) AVG 3Y
4.66
EARNINGS PER SHARE (EPS) AVG 5Y
4.19
EARNINGS PER SHARE (EPS) AVG 10Y
2.98
EARNINGS PER SHARE (EPS) AVG 15Y
2.54
EARNINGS PER SHARE (EPS) AVG 20Y
2.53
CURRENT VS TTM AVG
-45.49%
CURRENT VS 3Y AVG
-33.30%
CURRENT VS 5Y AVG
-25.78%
CURRENT VS 10Y AVG
+4.36%
CURRENT VS 15Y AVG
+22.57%
CURRENT VS 20Y AVG
+23.00%
Abbott Laboratories
Market Cap
$182.12B
Earnings Per Share (EPS)
3.11
TTM Avg
5.71
3Y Avg
4.66
5Y Avg
4.19
Market Cap
$180.83B
Earnings Per Share (EPS)
-2.67
TTM Avg
3.61
3Y Avg
3.85
5Y Avg
3.41
Market Cap
$197.87B
Earnings Per Share (EPS)
4.06
TTM Avg
3.38
3Y Avg
2.82
5Y Avg
2.39
Market Cap
$211.17B
Earnings Per Share (EPS)
16.09
TTM Avg
10.97
3Y Avg
11.67
5Y Avg
11.57
Market Cap
$144.11B
Earnings Per Share (EPS)
5.63
TTM Avg
5.20
3Y Avg
6.66
5Y Avg
6.73
Market Cap
$225.09B
Earnings Per Share (EPS)
18.59
TTM Avg
17.17
3Y Avg
16.90
5Y Avg
17.22
Market Cap
$132.26B
Earnings Per Share (EPS)
17.18
TTM Avg
6.69
3Y Avg
10.10
5Y Avg
9.99
Market Cap
$131.57B
Earnings Per Share (EPS)
4.54
TTM Avg
-0.48
3Y Avg
1.47
5Y Avg
0.84
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | $182.12B | 3.11 | 5.71 | 4.66 | 4.19 |
| Gilead Sciences, Inc. (GILD)vs › | $180.83B | -2.67 | 3.61 | 3.85 | 3.41 |
| Novo Nordisk A/S (NVO)vs › | $197.87B | 4.06 | 3.38 | 2.82 | 2.39 |
| Pfizer Inc. (PFE)vs › | $158.33B | 0.76 | 1.39 | 2.19 | 2.39 |
| Amgen Inc. (AMGN)vs › | $211.17B | 16.09 | 10.97 | 11.67 | 11.57 |
| Danaher Corporation (DHR)vs › | $144.11B | 5.63 | 5.20 | 6.66 | 6.73 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $225.09B | 18.59 | 17.17 | 16.90 | 17.22 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $132.26B | 17.18 | 6.69 | 10.10 | 9.99 |
| Bristol-Myers Squibb Company (BMY)vs › | $131.57B | 4.54 | -0.48 | 1.47 | 0.84 |
| Intuitive Surgical, Inc. (ISRG)vs › | $124.79B | 8.79 | 7.27 | 5.84 | 5.20 |
Trailing EPS (TTM)
$3.11
Forward EPS (Est.)
N/A
P/E Ratio
33.8
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 3.74 |
| 2024-12-31 | 7.67 |
| 2023-12-31 | 3.30 |
| 2022-12-31 | 3.94 |
| 2021-12-31 | 3.97 |
| 2020-12-31 | 2.52 |
| 2019-12-31 | 2.07 |
| 2018-12-31 | 1.35 |
| 2017-12-31 | 0.27 |
| 2016-12-31 | 0.95 |
| 2015-12-31 | 3.00 |
| 2014-12-31 | 1.51 |
| 2013-12-31 | 1.66 |
| 2012-12-31 | 3.78 |
| 2011-12-31 | 3.01 |
| 2010-12-31 | 2.99 |
| 2009-12-31 | 3.72 |
| 2008-12-31 | 3.16 |
| 2007-12-31 | 2.34 |
| 2006-12-31 | 1.12 |
| 2005-12-31 | 2.17 |
| 2004-12-31 | 2.07 |
| 2003-12-31 | 1.76 |
| 2002-12-31 | 1.79 |
| 2001-12-31 | 1.00 |
| 2000-12-31 | 1.80 |
| 1999-12-31 | 1.59 |
| 1998-12-31 | 1.52 |
| 1997-12-31 | 1.35 |
| 1996-12-31 | 1.21 |
